A new Checkpoint Inhibitor targeting PD-L1 is now in a myeloma Clinical Trial to be tested alone, with pomalidomide, or pomalidomide/dexamethasone. Checkpoint inhibitors take the “brakes” off the immune system so that it can be free to kill the myeloma cells. Durvalumab has already received fast-track approval by the FDA for bladder cancer for single-agent [...]